JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure―digest version―
…, S Kobayashi, Y Sakata, A Tanaka, K Toda… - Circulation …, 2019 - jstage.jst.go.jp
Heart Failure Society (JHFS). The working committee for this project includes members and
collaborators involved in the previous versions of the heart failure guidelines and members …
collaborators involved in the previous versions of the heart failure guidelines and members …
Paradoxical rescue from ischemic lung injury by inhaled carbon monoxide driven by derepression of fibrinolysis
T Fujita, K Toda, A Karimova, SF Yan, Y Naka, SF Yet… - Nature medicine, 2001 - nature.com
Carbon monoxide (CO) can arrest cellular respiration, but paradoxically, it is synthesized
endogenously by heme oxygenase type 1 (Ho-1) in response to ischemic stress. Ho-1–…
endogenously by heme oxygenase type 1 (Ho-1) in response to ischemic stress. Ho-1–…
[HTML][HTML] Japanese registry for mechanically assisted circulatory support: first report
…, K Nawata, T Nishinaka, Y Tanoue, K Toda… - The Journal of Heart and …, 2017 - Elsevier
Background In Japan, ventricular assist devices (VADs) have been used for patients with
severe heart failure as a bridge to transplantation (BTT) since 1992. However, it was not until …
severe heart failure as a bridge to transplantation (BTT) since 1992. However, it was not until …
Enhanced survival of transplanted human induced pluripotent stem cell–derived cardiomyocytes by the combination of cell sheets with the pedicled omental flap …
Background— Transplantation of cardiomyocytes that are derived from human induced
pluripotent stem cell–derived cardiomyocytes (hiPS-CMs) shows promise in generating new …
pluripotent stem cell–derived cardiomyocytes (hiPS-CMs) shows promise in generating new …
[HTML][HTML] Safety and efficacy of autologous skeletal myoblast sheets (TCD-51073) for the treatment of severe chronic heart failure due to ischemic heart disease
Y Sawa, Y Yoshikawa, K Toda, S Fukushima… - Circulation …, 2015 - jstage.jst.go.jp
Background: Poor survival outcomes for patients with severe heart failure (HF) and the donor
shortage for heart transplantation warrant the development of myocardial regenerative …
shortage for heart transplantation warrant the development of myocardial regenerative …
Phase I clinical trial of autologous stem cell–sheet transplantation therapy for treating cardiomyopathy
Background When transplanted into failing heart, autologous somatic tissue–derived cells
yield functional recovery via paracrine effects that enhance native regeneration. However, the …
yield functional recovery via paracrine effects that enhance native regeneration. However, the …
Clinical management for complications related to implantable LVAD use
K Toda, Y Sawa - General thoracic and cardiovascular surgery, 2015 - Springer
More than 250 continuous flow LVADs have been implanted in Japan during the last 3 years,
with 1-year survival rates of 90 %. These excellent results cannot be achieved without VAD …
with 1-year survival rates of 90 %. These excellent results cannot be achieved without VAD …
[HTML][HTML] Maturation of human induced pluripotent stem cell-derived cardiomyocytes by soluble factors from human mesenchymal stem cells
…, N Kashiyama, F Ohashi, T Toyofuku, K Toda… - Molecular Therapy, 2018 - cell.com
In this study, we proposed that the functionality or phenotype of differentiated cardiomyocytes
derived from human induced pluripotent stem cells (iPSC-CMs) might be modified by co-…
derived from human induced pluripotent stem cells (iPSC-CMs) might be modified by co-…
[PDF][PDF] Cardiomyocytes derived from MHC-homozygous induced pluripotent stem cells exhibit reduced allogeneic immunogenicity in MHC-matched non-human …
…, T Shiina, K Ogasawara, S Miyagawa, K Toda… - Stem cell reports, 2016 - cell.com
Induced pluripotent stem cells (iPSCs) can serve as a source of cardiomyocytes (CMs) to
treat end-stage heart failure; however, transplantation of genetically dissimilar iPSCs even …
treat end-stage heart failure; however, transplantation of genetically dissimilar iPSCs even …
Late aortic insufficiency related to poor prognosis during left ventricular assist device support
K Toda, T Fujita, K Domae, Y Shimahara… - The Annals of thoracic …, 2011 - Elsevier
BACKGROUND: Management of native aortic insufficiency (AI) during left ventricular assist
device (LVAD) support is challenging. We investigated the occurrence of de novo AI during …
device (LVAD) support is challenging. We investigated the occurrence of de novo AI during …